EGFR and hepatocellular carcinoma: Numerous studies have determined various factors associated with Lenvatinib resistance, such as Jin et al. found that inhibition of receptor tyrosine kinases by Lenvatinib leads to feedback activation of EGFR-PAK2-ERK5 pathways, which reduced the effectiveness of Lenvatinib in HCC 36.